The University of Pittsburgh has announced that it is part of a group of investors taking over an American subsidiary of the British company that helped clone Dolly the sheep. It is part of a trend in which university-based researchers are turning to private financing to engage in human embryonic stem cell experimentation and animal-to-human organ transplants.
Regenecor Holdings, the company now co-owned by the University, has purchased PPL Therapeutics, Inc., of Blacksburg, Va., a subsidiary of Britain's PPL Therapeutics Plc, the Dolly company. It raises genetically engineered pigs, develops stem cell technology and also polyclonal antibodies, laboratory-engineered drugs and vaccines based on immune system proteins.
“We want to see this technology move forward. We find the technology very promising,” said Lisa Rossi with the University of Pittsburgh Medical Center.
Click here to read the full article.
(This update courtesy of LifeSite News.)
